🔴 Heron Therapeutics is trading 6.12% down in pre-market with no clear company-specific catalyst

Heron Therapeutics is trading at $0.29, down 6.12% in pre-market, with no clear company-specific catalyst identified.

• The latest company announcement schedules third-quarter results for November 9; it does not report results or identify a new development.
• Broader market sentiment was cautious, but available evidence does not establish it as the cause of the stock’s move.
• Recent regular-session closes were narrowly clustered around $0.30–$0.31; reliable pre-market volume information was unavailable.